Back to top
more

VIVUS, Inc. (VVUS)

(Delayed Data from NSDQ)

$3.73 USD

3.73
58,550

+0.03 (0.81%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.83 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis Presents Data on Tafinlar-Mekinist Combination

by Zacks Equity Research

Novartis AG (NVS) announced results from a phase II study, BRF113220, on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

    Amgen (AMGN) Presents Positive Clinical Data on Cancer Drugs

    by Zacks Equity Research

    Amgen, Inc. (AMGN) presented encouraging results from a phase III study, evaluating its marketed drug Xgeva (denosumab) for an expanded indication at the American Society of Clinical Oncology.

      Radius (RDUS) Announces Positive Data on Breast Cancer Drug

      by Zacks Equity Research

      Radius Health, Inc. (RDUS) announced encouraging results from an ongoing phase I study on pipeline candidate elacestrant (RAD1901) in patients suffering from estrogen receptor positive (ER+) breast cancer.

        Swarup Gupta headshot

        5 Breakout Stocks Offering Stupendous Returns

        by Swarup Gupta

        Such stocks offer the prospect of above-average returns.

          Biogen/Ionis Spinraza Granted Marketing Authorization in EU

          by Zacks Equity Research

          Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy.

            Celgene & Acceleron Complete Enrollment on Thalassemia Drug

            by Zacks Equity Research

            Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) announced that the companies have completed target enrollment in the phase III studies, MEDALIST and BELIEVE on pipeline candidate luspatercept.

              Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU

              by Zacks Equity Research

              Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).

                BioMarin's (BMRN) Brineura Approved by European Commission

                by Zacks Equity Research

                BioMarin Pharmaceutical Inc. (BMRN) announced that the European Commission has approved Brineura (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2).

                  Aduro's Drug Gets Clearance by the FDA for Solid Tumors

                  by Zacks Equity Research

                  Aduro Biotech, Inc. (ADRO) announced that the FDA has cleared the Investigational New Drug application (IND) for its pipeline candidate ADU-S100 (MIW815).

                    Alder BioPharmaceuticals (ALDR) Looks Good: Stock Adds 10.7% in Session

                    by Zacks Equity Research

                    Alder BioPharmaceuticals' (ALDR) nearly 11% price rise in the last session increases the inquisitiveness for the stock. Read on to know more.

                      Teva's Migraine Candidate TEV-48125 Positive in Phase III

                      by Zacks Equity Research

                      Teva Pharmaceutical Industries Limited (TEVA) announced positive top-line results from a phase III study (HALO), evaluating its pipeline candidate, fremanezumab (TEV-48125) for prevention of chronic migraine (CM).

                        Alnylam's Givosiran Gets Breakthrough Therapy Status by FDA

                        by Zacks Equity Research

                        Alnylam Pharmaceuticals, Inc. (ALNY) announced that it has received Breakthrough Therapy designation from the FDA for pipeline candidate givosiran (ALN-AS1), for the prophylaxis of attacks in patients with acute hepatic porphyria (AHP).

                          Eli Lilly's (LLY) Cancer Drug Cyramza Positive in Phase III

                          by Zacks Equity Research

                          Eli Lilly and Company (LLY) announced positive results from a phase III study evaluating Cyramza for expanded use in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma.

                            Novo Nordisk's (NVO) Drug Gets FDA Approval for Hemophilia B

                            by Zacks Equity Research

                            Novo Nordisk (NVO) announced that the FDA has approved the Biologics License Application (BLA) for Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B.

                              Gilead Single Tablet Regiment for HIV Good in Phase III

                              by Zacks Equity Research

                              Gilead Sciences, Inc. (GILD) reported positive results on four phase III studies evaluating bictegravir in combination with FTC/TAF as a single tablet regimen for HIV infection.

                                Ligand (LGND) Signs Licensing Deal with xCella Biosciences

                                by Zacks Equity Research

                                Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide license agreement with drug discovery company xCella Biosciences, Inc.

                                  Pfizer's Trumenba Vaccine Approved by European Commission

                                  by Zacks Equity Research

                                  Pfizer Inc. (PFE) announced that its Trumenba vaccine received approval from the European Commission (EC) for active immunization of people aged 10 years and older for the prevention of invasive disease caused by Neisseria meningitidis serogroup B (MenB).

                                    Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose

                                    by Zacks Equity Research

                                    Merck & Co., Inc. (MRK) recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies.

                                      Bristol-Myers Partners Array to Investigate Cancer Candidate

                                      by Zacks Equity Research

                                      Bristol-Myers Squibb Company (BMY) and Array BioPharma (ARRY) entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's binimetinib in combination with the former's Opdivo and Opdivo + Yervoy regimen.

                                        Perrigo's (PRGO) Q1 Earnings Beat Estimates, Guidance Intact

                                        by Zacks Equity Research

                                        Perrigo Company plc (PRGO) reported first-quarter 2017 earnings of $1.05 per share which beat the Zacks Consensus Estimate of 98 cents per share by 7.1%.

                                          Falling Earnings Estimates Signal Weakness Ahead for Horizon Pharma (HZNP)

                                          by Zacks Equity Research

                                          One stock that you may want to consider dropping is Horizon Pharma Public Limited Company (HZNP), which has witnessed a significant price decline in the past four weeks

                                            Genomic Health (GHDX) Looks Good: Stock Adds 5.2% in Session

                                            by Zacks Equity Research

                                            Genomic Health (GHDX) was a big mover last session, as the company saw its shares rise over 5% on the day amid huge volumes.

                                              4 Reasons Why You Should Add Bayer Stock to Your Portfolio

                                              by Zacks Equity Research

                                              Bayer carries a Zacks Rank #2 (Buy) and a favorable VGM score of A.

                                                Will Regeneron's (REGN) Newly Approved Drugs Drive Growth?

                                                by Zacks Equity Research

                                                We believe approval of new drugs at Regeneron will lessen the company's dependence on Eylea.

                                                  MannKind Corporation (MNKD) Catches Eye: Stock Jumps 7%

                                                  by Zacks Equity Research

                                                  MannKind Corporation (MNKD) was a big mover last session, as the company saw its shares rise over 7% on the day amid huge volumes.